Objectives: To evaluate the feasibility and safety of the MIRUS system (Pall International, Sarl, Fribourg, Switzerland) for sedation with sevoflurane for postsurgical ICU patients and to evaluate atmospheric pollution during sedation. Design: Prospective interventional study. Setting: Surgical ICU. February 2016 to December 2016.
S edative agents are commonly administered to critically ill patients to increase tolerance toward invasive diagnostic procedures, avoid agitation, and encourage sleep. Many different protocols are applied, and the choice of agent and the way it is used varies widely between and within ICUs (1). However, there is growing concern surrounding the use of traditional analgo-sedative agents (benzodiazepines, propofol, and ketamine) (1) because of some side effects, including oversedation and drug tolerance, actual impact awakening times, duration of mechanical ventilation (MV), hemodynamic instability, delirium, neuropsychiatric disorders, and mortality (2, 3) . Recently, new interest has been directed toward alternative strategies, considering volatile anesthetics (VAs) as potential substitutes to standard IV agents (4, 5) . VAs have been administered in operating rooms for decades due to their advantageous pharmacokinetic and pharmacodynamic properties (6) and safety record. However, the technical challenge of needing vaporization prior to inhalation, having to scavenge systems to minimize atmospheric pollution and nonfamiliarity with this class of drugs among some intensivists, has limited the diffusion of VA in the ICUs. Their use has been applied mainly in selected cases of status asthmaticus, status epilepticus, and patients requiring high levels of sedation (5, 7, 8) . Recently, the MIRUS system (Pall International, Sarl, Fribourg, Switzerland, certified "Conformité Européenne" for use in anesthesia and the ICU), a new device manufactured for VA administration in critically ill patients, has been released, and clinical evaluation is ongoing (9, 10) . The present prospective interventional study has two main purposes: to evaluate the feasibility and safety related to inhaled sevoflurane delivered with the MIRUS system and to evaluate the atmospheric pollution with VA during sedation.
MATERIALS AND METHODS

Patients
After approval from the Ethical Committee (Prot/1073-SPE/14.157), patients scheduled for abdominal surgery and postoperative admittance in the ICU needing MV and sedation were included in the study between February 2016 and December 2016. Inclusion criteria were as follows: need for MV after surgery, age 18 years old or older, weight greater than or equal to 35 kg, and predicted tidal volume (Vt) greater than 300 mL. Exclusion criteria were as follows: lack of consent, patient with shock, neurologic impairment or preexisting neurologic disease, breastfeeding, history of malignant hyperthermia, acute kidney injury (according to Kidney Disease: Improving Global Outcomes criteria [11] ) or chronic renal failure, liver cirrhosis (any stage), surgery for kidney or liver diseases, and severe cardiac impairment (left ventricle ejection fraction < 40%). No limits of sedative duration, supposed or actual, were entailed in the inclusion/exclusion criteria.
Anesthesia Protocol
Intraoperative phase was conducted as routine with a total IV anesthesia. In case of open surgery (nonlaparoscopic and nonrobotic assisted), an epidural catheter was placed before induction of anesthesia. Anesthesia was performed using the following protocol: 1) induction with 0.5 μg/kg of sufentanil, 1-2 mg/kg of propofol (titrated on the depth of anesthesia monitor; Sedline Root Monitoring System; Masimo, Irvine, CA), and 0.9 mg/kg of rocuronium and 2) maintenance with propofol-remifentanil based on Patient State Index (Sedline Root Monitoring System; Masimo, Irvine, CA) of 25-50 and hemodynamics (invasive blood pressure and arterial pulse contour-based hemodynamic data; MostCare; Vygon, Padova, Italy). Postoperative sedation was switched from propofolremifentanil anesthesia to sevoflurane-morphine sedation.
Sedation and Analgesia Protocol
Patients admitted in surgical ICU were sedated with sevoflurane via the MIRUS system, which delivers the VA with an automatic target control of the end-tidal anesthetic concentration, connected to an Evita XLventilator (Dräger Medical, Lübeck, Germany). A MIRUS VA exchanger was placed between the closed suctioning system and the Y-piece of the ventilator breathing circuit (Fig. 1) . The MIRUS Reflector, applied just next to a humidifier/antibacterial filter, was specifically manufactured to recycle the expired VA. The expiration port of the ventilator was connected to a dedicated scavenger drained by a centralized vacuum waste gas system. Sedation was targeted to a Richmond Agitation Sedation Scale (RASS) from -3 (moderate sedation, movement of eye opening to voice, and no eye contact) to -5 (unarousable and no response to voice or physical stimulation) according to the clinical evaluation by adaptation of minimum alveolar concentration (MAC) in steps of 0.1 every 5 minutes (start at 0.5 MAC). A moderate to deep level of sedation was deemed appropriate at the end of abdominal surgery as the normalization of clinical variables and optimization of analgesia were main objectives before awakening and extubation. Sedation was interrupted as soon as the criteria for awakening and extubation had been reached, according to standard practice. Once the operator decided to awaken the patient, the Reflector was removed to avoid undesired release of VA entrapped in the Reflector. Awakening time was registered and defined as the time elapsed from sevoflurane interruption to the time the patient spontaneously opened his or her eyes and became fully cooperative. Postoperative pain was managed under routine practice with morphine, bolus of 0.1 mg/kg ideal body weight (IBW), 0.3 mg/kg IBW/d (continuous infusion) modified depending on patients' need, and paracetamol (1 g every 6 hr). An epidural catheter was used with chirocaine 0.125% and fentanyl 1 μg/mL at the dose of 5 mL/hr and modified depending on the patients' needs, according to standard practice. No neuromuscular blocking agents were used.
All the physicians and nursing staff involved in the study were trained with a 2-hour explanation on the MIRUS working characteristics and modalities.
Data Collection
The following data were collected from patient ICU arrival to extubation: 1) RASS was recorded hourly as a standard nurse practice, whereas PSI was continuously measured and hourly recorded at the same time of RASS evaluation for practical reasons. 2) VA and MV data from the MIRUS system at 1-hour intervals: MAC, inspired and expired sevoflurane fraction (FiSevo and Fe-Sevo, respectively), respiratory rate, Vt, minute ventilation, Pao 2 /Fio 2 , and Paco 2 . 3) Wake-up times (min). 4) Duration of sedation (hr) and VA consumption (mL/hr). 5) Hemodynamic data estimated by the MostCare (cardiac output [CO], stroke volume, and heart rate) at 1-hour intervals. 6) Norepinephrine infusion during sedation at 1-hour intervals. 7) Simplified Acute Physiology Score II, Sepsis-related Organ Failure Assessment score, WBC, RBC, hemoglobin concentration, platelet count, biomarkers of liver function data (prothrombin time), activated partial thromboplastin time, international normalized ratio, fibrinogen concentration, plasma alanine transaminase, indicators and biomarkers of renal function (urine output), plasma creatinine (Cr) concentration , plasma Cystatin C (Cys-C) concentration, and electrolytes (sodium, potassium, and calcium) 24 hours after the admission in ICU.
8) Side effects consequent to ineffective sedation (e.g. autoextubation, abnormal uncontrolled agitation), postextubation nausea, and hallucinations were also noted.
Atmospheric Pollution
Room air sevoflurane concentration (parts per million [ppm]) was sampled with the Photoacoustic Gas Monitor-INNOVA 1312 (LumaSense Technologies A/S, Ballerup, Denmark). Values below 5 ppm were considered acceptable (12) . Sampling sites and timing (30-s intervals; Fig. 1 ) were as follows: 1) Before sevoflurane delivery, with the MIRUS system next to the bed, a baseline measure (B) was obtained with the probe placed 15 cm up to the MIRUS switched on and ready to operate. 2) During sedation (S1) with the probe placed 15 cm up to the MIRUS system. 3) During sedation (S2) with the probe placed 15 cm from the Reflector.
Statistical Analysis
All data were analyzed using Stats Direct (version 6.1; Bonville Chase; Altrincham, Cheshire, United Kingdom). The ShapiroWilk test was used to test all data for normality. Continuous variables normally distributed were expressed as mean (sd) and those non-normally distributed as median (25th to 75th percentiles). Percentages were calculated for dichotomous data. Due to the observational nature of the study and its intrinsic meaning of feasibility and safety, no sample size calculation was performed but established according to previous similar studies (13, 14) .
RESULTS
A total of 62 patients (68.25 yr [12.83] ; 70.96% men) were enrolled in the study, and none were excluded. The results are summarized in Table 1 for patients' characteristics, Table 2 for sedation, hemodynamic and ventilation data, and pollution, and Hemodynamics remained stable over the study period: mean CO was 4.5 L/min (sd, 0.65) with minimal norepinephrine support (0.034 μg/kg/min [sd, 0.12]). No laboratory indicator of organ injury or dysfunction resulted. In particular, Cr, Cys-C, troponin I, and transaminase remained within the normal limits (Table 3) .
No deviation from the standard analgesic requirement was noted: epidural infusion (7 of 62; 11.2%) was always maintained according to the local protocol. No episodes of shivering, nausea, or vomiting were registered. There were no mortalities during the study. Richmond Agitation Sedation Scale 
DISCUSSION
This is the first study exploring sedation of ICU patients with the MIRUS system. The main findings were that sedation was feasible and safe since the atmospheric pollution resulted to be largely below the suggested thresholds (12) .
Sedation with sevoflurane was obtained in all the patients at the targeted sedation levels, and they were quickly awakened and extubated. The pharmacokinetic and pharmacodynamic properties of sevoflurane may explain our principal results: minimal dependence upon end-organ excretion or metabolism with no significant active metabolites (5), low blood solubility, and predominant pulmonary clearance. In addition, ICU sedation is achieved at approximately one third of the dosing administered for general anesthesia, although higher doses may be required, particularly in those patients requiring deeper sedation levels when clinically indicated. (14) compared midazolam and propofol with sevoflurane delivered via the Anesthesia Conserving Device (AnaConDa; Sedana Medical, Kungsgatan, Sweden) in 17 mixed ICU patients. In their study, the average consumption of sevoflurane targeted to a RASS less than or equal to −3 was 8.3 mL/hr (sd, 2.7) with a Fi-and Fe-Sevo of 1.06% (sd, 0.4) and 0.76% (sd, 0.31), respectively. Briefly, the AnaConDa system, first developed in 1999 and presented in 2004 (5, 7, 8, 14) , uses a specific anesthetic Reflector to save on the VA that is pumped by syringe (isoflurane or sevoflurane can be used but not desflurane due to its low boiling point) into an evaporator (9, 10) . Until now, the vast majority of experience with the use of VA in ICU patients comes from this system (6, 9, 10, 13, 15). The MIRUS system seems to represent a step forward due to some interesting technical properties: first, it can deliver desflurane (potential advantage of desflurane include the fastest onset/offset among the VAs), which cannot be used with a syringe pump because of the low boiling point (sevoflurane and isoflurane can also be used); second, the MIRUS comprises a monitor for gas concentration, pressure, and flow measurements (AnaConDa, an external gas monitor, must be used) with high accuracy and precision of the end-tidal concentrations (10); third, the MIRUS has its own control unit for determination of the end-tidal VA concentration target-controlled administration (an external gas monitor or a syringe pump is not needed). The MIRUS system consists of a main unit, with a VA reservoir connected to an interface by a multilumen cable for gas injection and for measuring gas pressure, flow, and concentration (10) . The system is connected to the respiration circuit between the Y-piece and the tracheal tube, with a Reflector and a heat and moisture exchanger and microbiological filter. Airway pressure and gas flow are continuously measured and displayed on the screen of the control unit (10) . The end-tidal concentration is automatically regulated to a target value by the main control system according to the MAC set in the machine. Three different speed levels of wash-in and wash-out of the VA can be set by selecting one of three symbols (slow: tortoise, moderate: hare, and high: cheetah). The moderate speed level was applied in the present study. During the sedation period, spontaneous breathing was obtained, avoiding agitation or respiratory dyssynchrony without abnormal levels of Paco 2 , with a median minute ventilation of 7.52 L/min (IQR, 6.38-8.68), and no relevant impairments in hemodynamics were evaluated during sevoflurane administration.
In light of our study, the MIRUS system seems to expand the possibility of using alternative sedation strategies in ICU patients. With rising concerns over adverse effects associated with current sedation practice (propofol and benzodiazepines), alternative approaches are recommended by the current Society of Critical Care Medicine within the guidelines (1). Oversedation from high doses or reduced metabolism and clearance of propofol or benzodiazepines (usually associated with opioids) eventually impact awakening times, duration of MV, hemodynamics and mortality due to the occurrence of delirium, drug tolerance, and long-term neuropsychiatric (1, 3, 16) . The American guidelines do not mention inhalational anesthetic; however, interestingly, the more recently updated German "Evidence-and Consensus-Based Guideline for the Management of Delirium, Analgesia, and Sedation in Intensive Care Medicine. Revision 2015 (DASGuideline 2015)," indicates that "aside from propofol and benzodiazepines, VAs are also feasible options in the absence of contraindications" (4) . Furthermore, the guidelines clearly state that "volatile anesthetics may be considered for mechanically ventilated patients, if short wake-up times are desired" (4) . Rapid onset time (without effects of tolerance or tachyphylaxis), rapid wash-out via pulmonary exhalation with minimal hepatic metabolism (sevoflurane 5%), and production of no significant active metabolites are among the characteristics of VA (6, 17, 18) . In our patient population, awakening time was particularly short (4 min [IQR, 2.2-5]), which is less than for patients, as described in literature, who received IV sedation with propofol (13 min) (18) (19) (20) and much less than for those who received midazolam (18, 20, 21) . Furthermore, fast awakening and extubation times have been recently confirmed in a meta-analysis including 934 patients (19) . In addition, a recent prospective analysis of a large database on surgical patients demonstrated that higher intraoperative VA doses were strongly associated with lower odds of postoperative respiratory complications, lower 30-day mortality, and lower cost of hospital care. The authors speculated that sedation with VA administered in ICU patients may have protective respiratory effects (22) . Finally, safety is a key aspect in sedation practice: hemodynamic and respiratory stability was observed with no signs of organ dysfunction, and an excellent safety profile has emerged by analyzing the room air at different site points. Due to reported relationships between VA pollution and infertility and spontaneous abortions, gas scavenging of expired VA has become routine in operating rooms to ensure that occupational exposition levels remain below the recommended national safety standards (12) . The dedicated scavenger ensuring levels of air pollution five to 10 times lower than those indicated in 2016 by many European countries (5-20 ppm in Finland, Sweden, Denmark, Norway, and Austria) as a limit threshold (12) confirm the high safety levels of the MIRUS system. Finally, compound A, a potentially nephrotoxic product released from degradation of sevoflurane by carbon dioxide absorbents (23) , can be excluded as a source of renal injury in our patients since a Co 2 adsorber is not part of the MIRUS system.
The present study has some limitations. First, the main objective was to evaluate the feasibility and safety of sevoflurane delivery with the MIRUS system, and the population of enrolled patients was very homogenous (postsurgical without organ insufficiency and/or hemodynamic instability). A broader mix of surgical-medical patients with comorbidities should be included in future studies. Second, a relatively short duration of sedation was observed in this study, and more extended sevoflurane administration should be explored. Third, the selected population and the characteristics of the study design prevented exploration of other important issues surrounding sedation, including end-organ damage or protection, effects on delirium, and the prevalence of other neuropsychiatric disorders.
CONCLUSIONS
Although key clinical questions of this technology are yet to be explored, our observations indicate that the MIRUS system is a promising alternative for sedation with sevoflurane of ICU patients. Larger studies, extended to a more heterogeneous population of patients undergoing longer sedation, are needed to confirm these observations.
